Moleac Pte Ltd wins SBR National Business Award for Pharmaceuticals
Moleac, a biopharmaceutical company based in Singapore, wins SBR National Business Award for Pharmaceuticals.
Moleac is dedicated to finding, developing, and commercializing new medicines for the unmet medical needs of patients suffering from central nervous system diseases and injuries. From stroke, traumatic brain injury (TBI) and dementia, the company’s main goal is to help people with disabilities after brain injuries or neurodegenerative diseases—as well as their families—reconnect with their lives.
Stroke is considered one of the most debilitating diseases, afflicting over 17 million people each year. Stroke not only endangers the lives of stroke survivors but also burdens families with significant caretaking and financial expenses. Despite the use of revascularization treatments in AIS, a huge number of stroke survivors will suffer from disabilities that will cause a substantial impact on their day-to-day lives.
Moleac has pioneered a new drug development approach that looks at sources of innovation from natural medicine, thus considerably shortening drug development cycle time and investment to bring medicine to post-stroke recovery patients. An official announcement is published by SBR, you may access it HERE.